TY - JOUR
T1 - A randomized placebo-controlled trial of omega-3 and sertraline in depressed patients with or at risk for coronary heart disease
AU - Carney, Robert M.
AU - Freedland, Kenneth E.
AU - Rubin, Eugene H.
AU - Rich, Michael W.
AU - Steinmeyer, Brian C.
AU - Harris, William S.
N1 - Funding Information:
This study was funded by Grant Number RO1 HL117805 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Atrium Innovations Inc provided the eicosapentaenoic acid and matching placebo capsules for the trial.
Funding Information:
Inc. DrHarrisis the President of OmegaQuant member ofhis family is a stockholder in Pfizer 1. Carney RM, Freedland KE. Depression and Gen Hosp Psychiatry. 2011;33(3):203–216.PubMed CrossRef Analytics,LLC.Drs Freedland, Rubin, andRich coronary heart disease. Nat Rev Cardiol. Berkman LF, Blumenthal J, Burg M, et al; andMr Steinmeyerhave no potential conflicts of 2017;14(3):145–155.PubMed CrossRef Enhancing Recovery in Coronary Heart Disease interesttoreport. 2. Lichtman JH, Froelicher ES, Blumenthal JA, et Patients Investigators (ENRICHD). Effects of al; American Heart Association Statistics treating depression and low perceived social Funding/support:This study was funded by Grant Committee of the Council on Epidemiology support on clinical events after myocardial Number RO1 HL117805 from the National Heart, and Prevention and the Council on infarction: the Enhancing Recovery in Coronary Lung, and Blood Institute, National Institutes of Cardiovascular and Stroke Nursing. Depression Heart Disease Patients (ENRICHD) Randomized Health,Bethesda,Maryland.AtriumInnovationsInc as a risk factor for poor prognosis among Trial. JAMA. 2003;289(23):3106–3116.PubMed CrossRef provided the eicosapentaenoic acid and matching patients with acute coronary syndrome: Glassman AH, O’Connor CM, Califf RM, et al; placebo capsules for the trial. systematic review and recommendations: a Sertraline Antidepressant Heart Attack Role of the sponsor: Neither the National Institutes scientific statement from the American Heart Randomized Trial (SADHEART) Group. of Health nor Atrium Innovations Inc had a role in Association. Circulation. Sertraline treatment of major depression in
Publisher Copyright:
© Copyright 2019 Physicians Postgraduate Press, Inc.
PY - 2019
Y1 - 2019
N2 - Objective: Studies of depressed psychiatric patients have suggested that antidepressant efficacy can be increased by adding eicosapentaenoic acid (EPA), one of the omega-3 fatty acids found in fish oils. The purpose of this study was to determine whether the addition of EPA improves the response to sertraline in depressed patients with or at high risk for coronary heart disease (CHD). Methods: Between May 2014 and June 2018, 144 patients with DSM-5 major depressive disorder seen at the Washington University School of Medicine with or at high risk for CHD were randomized to receive either 50 mg/d of sertraline and 2 g/d of EPA or 50 mg/d of sertraline and corn oil placebo capsules for 10 weeks. The Beck Depression Inventory II (BDI-II) was the primary outcome measure. Results: After 10 weeks of treatment, there were no differences between the arms on the mean baselineadjusted BDI-II (placebo, 10.3; EPA, 12.1; P = .22), the 17- item Hamilton Depression Rating Scale (placebo, 7.2; EPA, 8.0; P = .40), or the 10-week remission rate (BDI-II score ≤ 8: placebo, 50.6%; EPA, 46.7%; odds ratio = 0.85; 95% CI, 0.43 to 1.68; P = .63). Conclusions: Augmentation of sertraline with 2 g/d of EPA for 10 weeks did not result in greater improvement in depressive symptoms compared to sertraline and corn oil placebo in patients with major depressive disorder and CHD or CHD risk factors. Identifying the characteristics of cardiac patients whose depression may benefit from omega-3 and clarifying the pathways linking omega-3 to improvement in depression symptoms are important directions for future research.
AB - Objective: Studies of depressed psychiatric patients have suggested that antidepressant efficacy can be increased by adding eicosapentaenoic acid (EPA), one of the omega-3 fatty acids found in fish oils. The purpose of this study was to determine whether the addition of EPA improves the response to sertraline in depressed patients with or at high risk for coronary heart disease (CHD). Methods: Between May 2014 and June 2018, 144 patients with DSM-5 major depressive disorder seen at the Washington University School of Medicine with or at high risk for CHD were randomized to receive either 50 mg/d of sertraline and 2 g/d of EPA or 50 mg/d of sertraline and corn oil placebo capsules for 10 weeks. The Beck Depression Inventory II (BDI-II) was the primary outcome measure. Results: After 10 weeks of treatment, there were no differences between the arms on the mean baselineadjusted BDI-II (placebo, 10.3; EPA, 12.1; P = .22), the 17- item Hamilton Depression Rating Scale (placebo, 7.2; EPA, 8.0; P = .40), or the 10-week remission rate (BDI-II score ≤ 8: placebo, 50.6%; EPA, 46.7%; odds ratio = 0.85; 95% CI, 0.43 to 1.68; P = .63). Conclusions: Augmentation of sertraline with 2 g/d of EPA for 10 weeks did not result in greater improvement in depressive symptoms compared to sertraline and corn oil placebo in patients with major depressive disorder and CHD or CHD risk factors. Identifying the characteristics of cardiac patients whose depression may benefit from omega-3 and clarifying the pathways linking omega-3 to improvement in depression symptoms are important directions for future research.
UR - http://www.scopus.com/inward/record.url?scp=85067521958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067521958&partnerID=8YFLogxK
U2 - 10.4088/JCP.19m12742
DO - 10.4088/JCP.19m12742
M3 - Article
C2 - 31163106
AN - SCOPUS:85067521958
VL - 80
JO - Diseases of the Nervous System
JF - Diseases of the Nervous System
SN - 0160-6689
IS - 4
M1 - 19m12742
ER -